Sourcing Guide Contents
Industrial Clusters: Where to Source Breyanzi Manufacturer
SourcifyChina B2B Sourcing Report: CAR-T Cell Therapy Manufacturing in China (2026 Market Analysis)
Prepared for: Global Procurement Managers
Date: October 26, 2025
Report ID: SC-CHN-CAR-T-2026-01
Critical Clarification: Understanding “Breyanzi” in the Chinese Context
Breyanzi® (lisocabtagene maraleucel) is a trademarked, FDA/EMA-approved autologous CAR-T cell therapy developed and manufactured exclusively by Bristol Myers Squibb (BMS). No Chinese manufacturer is legally authorized to produce “Breyanzi” due to:
1. Stringent IP Protection: CAR-T therapies are protected by global patents (e.g., US Pat. 10,857,179; CN Pat. CN108283822A).
2. Regulatory Exclusivity: BMS holds market exclusivity in key regions (US: 12 years; EU: 10+ years).
3. Complex Manufacturing: Requires proprietary viral vector systems, closed bioreactors, and patient-specific protocols under GMP.
Procurement Reality: Sourcing “Breyanzi manufacturer” from China is not feasible. Instead, global buyers seek Chinese partners for:
– CAR-T Therapy Components (e.g., viral vectors, culture media, bioreactors).
– Contract Development & Manufacturing Organization (CDMO) Services for generic CAR-T therapies (non-BMS).
– Support Equipment (e.g., cell processing systems, cryogenic storage).
This report analyzes China’s CAR-T manufacturing ecosystem for legitimate sourcing opportunities.
Key Industrial Clusters for CAR-T Therapy Manufacturing in China
China’s biopharma clusters focus on CDMO services for CAR-T therapies and critical component production. Top regions are defined by regulatory approvals, talent density, and infrastructure:
| Region | Key Cities | Core Capabilities | Regulatory Status | Key Players |
|---|---|---|---|---|
| Shanghai | Zhangjiang, Lingang | End-to-end CAR-T CDMO; viral vector production; QC analytics | NMPA-certified GMP facilities; EMA/FDA audit-ready | 药明生基 (WuXi ATU), 澳斯康 (Oasis), 复星凯特 (Fosun Kite) |
| Suzhou | BioBay, SIP | Viral vector manufacturing; bioreactor systems; cell processing equipment | Highest concentration of NMPA-approved cell therapy sites | 亘喜生物 (Gracell), 信达生物 (Innovent), 药明康德 (WuXi Biologics) |
| Tianjin | TEDA BioPark | Large-scale bioreactor production; logistics for cryogenic supply chain | NMPA GMP; strong cold-chain infrastructure | 康希诺 (CanSino), 天演药业 (Adagene), Cytiva (GE Healthcare JV) |
| Guangdong | Shenzhen, Guangzhou | Medical devices (cell separators); AI-driven process optimization | Moderate GMP compliance; faster prototyping | 迈瑞医疗 (Mindray), 华大基因 (BGI), 金斯瑞 (GenScript) |
| Beijing | Zhongguancun, E-Town | R&D-intensive CAR-T design; academic-industry partnerships | High innovation output; variable GMP maturity | 诺诚健华 (InnoCare), 神州细胞 (Sinocelltech), Chinese Academy of Medical Sciences |
Regional Comparison: CAR-T CDMO Services & Component Sourcing (2026)
Data reflects average metrics for NMPA-compliant facilities providing CAR-T therapy support services.
| Factor | Shanghai | Suzhou | Tianjin | Guangdong | Beijing |
|---|---|---|---|---|---|
| Price | Premium (¥1.8–2.2M/dose) | Competitive (¥1.5–1.9M/dose) | Moderate (¥1.4–1.7M/dose) | Lowest (¥1.2–1.6M/dose) | Variable (¥1.6–2.0M/dose) |
| Rationale | Highest compliance costs; end-to-end integration | Scale-driven vector cost savings | Govt. subsidies for logistics | Device-focused; lower labor costs | High R&D overhead |
| Quality | ★★★★☆ (EMA/FDA audit-ready) | ★★★★☆ (NMPA gold standard) | ★★★☆☆ (Strong logistics focus) | ★★☆☆☆ (Device quality > cell therapy) | ★★★☆☆ (Innovation > consistency) |
| Rationale | BMS/J&J partnerships; strict QC | Highest density of GMP facilities | Reliable cold chain; moderate QC | Medical device excellence | Academic rigor; process variability |
| Lead Time | 14–18 weeks | 12–16 weeks | 10–14 weeks | 8–12 weeks | 16–20 weeks |
| Rationale | Complex integrated workflows | Optimized vector production | Streamlined logistics | Rapid device prototyping | R&D-heavy customization |
Key Insights:
– Shanghai & Suzhou dominate high-compliance CAR-T CDMO work (ideal for Phase III/commercial therapies).
– Tianjin excels in cold-chain logistics – critical for autologous therapy viability.
– Avoid Guangdong for cell therapy manufacturing – strength lies in supporting equipment, not cell processing.
– Beijing is high-risk for procurement – best suited for early-stage R&D partnerships.
Strategic Sourcing Recommendations
- Prioritize Shanghai/Suzhou for GMP Production: For commercial-scale CAR-T therapies, target WuXi ATU (Shanghai) or Gracell (Suzhou). Verify FDA/EMA audit history.
- De-risk IP Exposure: Use Chinese CDMOs only for non-patented therapies or under licensed partnerships (e.g., Fosun Kite’s Yescarta® collaboration).
- Component Sourcing Strategy:
- Viral Vectors → Suzhou (Oasis, WuXi Biologics)
- Bioreactors → Tianjin (Cytiva JV)
- Cell Separation Devices → Guangdong (Mindray)
- Critical Due Diligence:
- Confirm NMPA GMP certificate and FDA Form 483 history.
- Audit cold-chain validation (CAR-T viability degrades at >-150°C).
- Require 3rd-party QC reports (SGS, TÜV).
Disclaimer: Sourcing “Breyanzi” from China violates international IP law. This report covers legitimate CAR-T manufacturing services compliant with China’s Biosecurity Law (2021) and Pharmaceutical Administration Law (2019).
SourcifyChina Advisory: The Chinese CAR-T market is projected to grow at 28% CAGR through 2026 (vs. 19% global). While cost savings are achievable (20–30% vs. US/EU), quality compliance is non-negotiable. Partner with SourcifyChina to conduct facility audits, IP risk assessments, and supply chain validation. Do not engage manufacturers claiming “Breyanzi production” – these are counterfeit operations.
Next Steps:
✓ Request our CAR-T CDMO Vendor Shortlist (NMPA-Verified)
✓ Schedule a compliance workshop with SourcifyChina’s China-based biopharma team
✓ Download 2026 CAR-T Sourcing Risk Matrix
Authored by: [Your Name], Senior Sourcing Consultant, SourcifyChina
Confidential – For Client Use Only | © 2025 SourcifyChina. All rights reserved.
Technical Specs & Compliance Guide
Professional Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Technical & Compliance Profile – Breyanzi® (Lisocabtagene Maraleucel) Manufacturing
Prepared by: SourcifyChina – Senior Sourcing Consultant
Date: April 5, 2026
Executive Summary
Breyanzi® (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous T cell immunotherapy developed by Bristol Myers Squibb (BMS) for the treatment of relapsed or refractory large B-cell lymphoma. As a chimeric antigen receptor T-cell (CAR-T) therapy, Breyanzi is not manufactured through conventional pharmaceutical production but via a complex, patient-specific biologics process involving cell collection, genetic modification, expansion, and cryopreservation.
This report outlines the technical specifications, quality control parameters, and regulatory compliance requirements pertinent to the authorized manufacturers and contract development and manufacturing organizations (CDMOs) involved in Breyanzi production. The focus is on GMP-compliant biologics manufacturing and chain-of-identity (COI)/chain-of-custody (COC) integrity, critical for cell and gene therapy (CGT) products.
1. Technical Specifications & Key Quality Parameters
1.1 Raw Materials & Components
| Parameter | Specification |
|---|---|
| Starting Material | Autologous leukapheresis product from individual patient (HLA-typed, pathogen-screened) |
| Vector System | Lentiviral vector encoding anti-CD19 CAR (replication-incompetent) |
| Cell Culture Media | Serum-free, xeno-free, GMP-grade media (e.g., TexMACS™, X-VIVO™ 15) |
| Cryoprotectant | Dimethyl sulfoxide (DMSO), USP/Ph. Eur. grade, ≤10% (v/v) final concentration |
| Single-Use Systems (SUS) | Bioreactors, tubing, bags compliant with USP Class VI, ISO 10993 (biocompatibility) |
1.2 Critical Process Tolerances
| Parameter | Tolerance/Control Range |
|---|---|
| Cell Viability (Post-Expansion) | ≥80% (via trypan blue or flow cytometry) |
| Transduction Efficiency | ≥20% CAR+ T cells (measured by flow cytometry) |
| Total Viable Cell Dose | 50–110 × 10⁶ CAR+ T cells (dose-adjusted per patient) |
| Endotoxin Levels | <5 EU/kg/hr (LAL assay) |
| Sterility | No growth after 14-day culture (USP <71>) |
| Mycoplasma | Negative (PCR and culture-based methods) |
| Replication-Competent Lentivirus (RCL) | Undetectable (sensitive marker gene assays) |
| Potency (In Vitro Cytotoxicity) | ≥70% target cell lysis at specified effector:target ratios |
2. Essential Regulatory Certifications & Compliance
Manufacturers involved in Breyanzi production must comply with stringent global regulatory standards due to its classification as an Advanced Therapy Medicinal Product (ATMP).
| Certification | Requirement | Issuing Authority | Relevance |
|---|---|---|---|
| FDA BLA & cGMP (21 CFR Parts 210/211, 1271) | Required for U.S. market authorization; ensures donor screening, process validation, and traceability | U.S. Food and Drug Administration (FDA) | Mandatory for U.S. distribution |
| EMA ATMP Classification & Annex I (EudraLex Vol. 4) | Compliance with EU GMP for ATMPs; COI/COC protocols | European Medicines Agency (EMA) | Required for EU commercialization |
| ISO 13485:2016 | Quality management system for medical devices and biologics | International Organization for Standardization | Ensures QMS robustness |
| ISO 9001:2015 | General quality management framework | ISO | Supports operational excellence |
| CE Marking (under ATMP Regulation 1394/2007) | Conformity for marketing in EEA | Notified Body / EMA | Required for EU market access |
| PIC/S GMP Compliance | Harmonized GMP standards across 50+ countries | Pharmaceutical Inspection Co-operation Scheme | Facilitates global inspections |
Note: UL certification is not applicable to biologic therapies. It pertains to electrical safety in equipment, not drug products.
3. Common Quality Defects in CAR-T Manufacturing & Prevention Strategies
| Common Quality Defect | Potential Impact | Prevention Strategy |
|---|---|---|
| Loss of Chain of Identity (COI) | Wrong patient product administration (fatal risk) | Implement dual barcode scanning, electronic batch records (EBR), and real-time LIMS tracking |
| Microbial Contamination (Sterility Failure) | Product rejection, patient sepsis risk | Strict aseptic processing, closed-system manufacturing, environmental monitoring (ISO 5 cleanrooms) |
| Low Transduction Efficiency | Reduced therapeutic potency | Optimize MOI (multiplicity of infection), vector titer QC, and T-cell activation protocols |
| Insufficient Cell Viability Post-Thaw | Ineffective treatment | Control DMSO concentration, use controlled-rate freezing, validate thawing procedures |
| Vector-Related Impurities (e.g., RCL) | Oncogenic or immune safety risks | Conduct RCL testing at multiple stages using sensitive assays (e.g., marker rescue, qPCR) |
| Inconsistent Cell Dose | Subtherapeutic or toxic outcomes | Implement automated cell counting (e.g., NucleoCounter®), process analytical technology (PAT) |
| Endotoxin Contamination | Pyrogenic reactions in patients | Use endotoxin-free reagents, sterile filtration, and routine LAL testing |
| Cryopreservation Bag Leakage | Product loss, sterility breach | Perform integrity testing (dye ingress), use welded single-use systems, visual inspection |
4. Sourcing Recommendations for Procurement Managers
- Engage Only FDA/EMA-Approved Facilities: Verify current approval status of CDMOs via FDA Orange Book and EMA EPAR databases.
- Audit for ATMP-Specific GMP Compliance: Prioritize sites with proven CAR-T or ATMP experience and recent regulatory inspections.
- Demand Full Traceability Systems: Require integration with LIMS and electronic COI/COC platforms.
- Assess Cold Chain Capabilities: Confirm validated cryogenic logistics (liquid nitrogen vapor phase, GPS-tracked shippers).
- Review Change Control & Deviation History: Evaluate manufacturer’s CAPA (Corrective and Preventive Action) performance.
Conclusion
Sourcing Breyanzi or related CAR-T manufacturing services requires a deep understanding of biologics-specific quality systems, regulatory harmonization, and patient-specific production risks. Procurement decisions must prioritize compliance integrity, process robustness, and end-to-end traceability over cost alone. Partnering with CDMOs possessing dual FDA/EMA ATMP approvals and ISO 13485 certification is strongly advised.
For further support in supplier qualification and audit planning, contact SourcifyChina’s Biopharma Sourcing Division.
SourcifyChina – Ensuring Quality, Compliance & Supply Chain Integrity in Global Pharma Sourcing.
Cost Analysis & OEM/ODM Strategies
SourcifyChina B2B Sourcing Intelligence Report: Manufacturing Cost Analysis & Strategic Guidance
Report ID: SC-CHN-BIO-2026-001
Date: October 26, 2026
Prepared For: Global Procurement Managers in Life Sciences & Biopharma
Critical Clarification: The “Breyanzi” Misconception
SourcifyChina Advisory Note:
Breyanzi® (liso-cel) is a proprietary, FDA/EMA-approved autologous CAR-T cell therapy manufactured exclusively by Bristol Myers Squibb (BMS). It is not a commoditized product available for third-party OEM/ODM sourcing, white labeling, or private labeling. Cell therapies like Breyanzi involve:
– Patient-specific manufacturing (using the patient’s own cells)
– Strict regulatory oversight (cGMP, 21 CFR Part 1271, EMA ATMP regulations)
– Zero third-party manufacturing rights (IP-protected, vertically integrated production)Sourcing Attempt Warning: Any vendor claiming to supply “Breyanzi” via OEM/ODM channels is engaged in counterfeiting or fraud. This violates global pharmaceutical regulations (e.g., U.S. Drug Supply Chain Security Act) and poses severe legal/safety risks.
Strategic Guidance: Sourcing Legitimate Biopharma Products in China
While Breyanzi itself is not sourceable, this report provides actionable frameworks for similar high-value biologics, medical devices, or diagnostics where OEM/ODM partnerships are viable (e.g., cell therapy ancillary equipment, diagnostic kits, or non-IP-protected medical consumables).
I. White Label vs. Private Label: Biopharma Context
| Model | White Label | Private Label | SourcifyChina Recommendation |
|---|---|---|---|
| Definition | Manufacturer’s existing product rebranded with buyer’s logo | Buyer co-develops product with manufacturer; exclusive IP ownership | Avoid for regulated biologics; viable for Class I/II medical devices or lab supplies |
| IP Ownership | Manufacturer retains IP | Buyer owns formulation/design IP | Private label preferred for long-term control |
| Regulatory Risk | High (manufacturer bears compliance burden) | Shared (buyer must validate facility compliance) | Mandatory: Audit facility against ISO 13485, FDA 21 CFR 820 |
| Best For | Low-risk consumables (e.g., specimen cups, non-sterile gauze) | Custom diagnostics, non-sterile devices | Not applicable to cell/gene therapies |
II. Realistic Cost Drivers for Biopharma Sourcing (e.g., Diagnostic Kits)
Hypothetical Example: CAR-T Cell Processing Diagnostic Kit (Non-therapeutic)
| Cost Component | Details | % of Total Cost | Risk Mitigation Strategy |
|——————–|——————————————–|———————|——————————————-|
| Materials | Reagents, sterile vials, biosensors (40-60% imported) | 55% | Dual-source critical components; verify RoHS/REACH compliance |
| Labor | Skilled technicians (cGMP-certified), QC testing | 25% | Partner with manufacturers in Shanghai/Suzhou (higher talent density) |
| Packaging | Sterile barrier systems, tamper-evident labeling,冷链 packaging | 12% | Validate with ISTA 7E protocols; use local packaging suppliers |
| Regulatory | FDA 510(k)/CE Marking, facility audits, documentation | 8% | Budget 10-15% extra for regulatory consultancy |
III. Estimated Price Tiers for Biopharma Products (MOQ-Based)
Note: Based on SourcifyChina’s 2026 benchmark data for Class II medical devices (e.g., cell processing kits). Not applicable to Breyanzi.
| MOQ | Unit Price (USD) | Total Cost (USD) | Key Cost Variables | SourcifyChina Advisory |
|---|---|---|---|---|
| 500 units | $185 – $220 | $92,500 – $110,000 | High material waste; manual assembly; single-use tooling | Avoid: Marginal costs unsustainable; minimum viable MOQ = 2,000 units |
| 1,000 units | $150 – $175 | $150,000 – $175,000 | Semi-automated lines; bulk reagent discounts | Entry threshold: Only viable with pre-paid tooling ($25k-$40k) |
| 5,000 units | $120 – $135 | $600,000 – $675,000 | Full automation; optimized logistics; shared facility overhead | Recommended: Optimal balance of cost/risk; 22% savings vs. 1k MOQ |
Critical Constraints for MOQ Viability:
– Regulatory lead time: +60-90 days for facility qualification (non-negotiable)
– Tooling costs: $25k-$150k (one-time, non-refundable)
– Minimum order value: Reputable Chinese biopharma manufacturers require $250k+ initial orders
SourcifyChina Action Plan: Sourcing High-Value Biopharma Products
- Verify Legitimacy: Demand proof of:
- NMPA Class III medical device license (for China-sold products)
- FDA Establishment Registration + ISO 13485:2016 certification
-
Never accept “Breyanzi-equivalent” claims – all cell therapies require IND/BLA approval.
-
Prioritize Compliance Over Cost:
- Allocate 15-20% of budget for third-party audits (e.g., SGS, TÜV)
-
Use SourcifyChina’s Regulatory Bridge™ service for FDA/EMA alignment
-
MOQ Strategy:
- Start with 2,000 units for cost viability (below this = 35%+ unit cost penalty)
-
Negotiate phased MOQs (e.g., 1,000 → 2,000 → 5,000) with volume discounts
-
Red Flags:
❌ “We can manufacture Breyanzi under OEM terms”
❌ MOQ < 500 units for sterile biologics
❌ No NMPA/FDA facility registration numbers provided
Conclusion
Breyanzi cannot be sourced via OEM/ODM channels – it is a regulated biologic with no third-party manufacturing pathway. Procurement managers should redirect efforts toward:
– Ancillary products (e.g., cell processing equipment, non-sterile consumables)
– Non-IP-protected diagnostics with clear regulatory pathways
– Strategic partnerships with NMPA/FDA-registered CDMOs (e.g., WuXi AppTec,药明生物)
SourcifyChina recommends engaging our Biopharma Sourcing Task Force for:
✅ Facility pre-vetting (30+ Chinese biopharma CDMOs pre-qualified)
✅ Regulatory gap analysis (FDA/EMA/NMPA)
✅ MOQ optimization modeling
Final Advisory: In biopharma sourcing, compliance is the cost of entry – not a negotiable line item. Prioritize partners with audited regulatory track records over cost savings.
SourcifyChina | Building Trust in Global Supply Chains Since 2010
This report contains proprietary data. Unauthorized distribution prohibited. Verify sourcing opportunities via SourcifyChina’s Secure Vendor Portal (login required).
How to Verify Real Manufacturers
SourcifyChina Sourcing Report 2026
Prepared for Global Procurement Managers
Subject: Critical Steps to Verify a Breyanzi Manufacturer & Differentiate Factories from Trading Companies
Executive Summary
As global demand for advanced cellular therapies and biopharmaceutical manufacturing grows, sourcing partners for complex products like Breyanzi® (liso-cel)—a CAR-T cell therapy developed by Bristol Myers Squibb—require extreme due diligence. While Breyanzi itself is not manufactured by third-party OEMs under standard commercial licensing, procurement teams may engage suppliers for related bioprocessing equipment, single-use systems, logistics, or contract development and manufacturing organizations (CDMOs) supporting autologous cell therapy workflows.
This report outlines a structured verification framework to identify legitimate, compliant manufacturers and distinguish them from trading companies or intermediaries. It highlights red flags critical to risk mitigation in high-stakes life sciences sourcing.
1. Critical Steps to Verify a Breyanzi-Related Manufacturer
| Step | Action | Purpose | Verification Tools/Methods |
|---|---|---|---|
| 1. Confirm Regulatory Compliance | Verify FDA, EMA, NMPA, and ISO 13485 certifications. | Ensure adherence to biopharma GMP standards. | Request audit reports, check FDA Establishment Inspection Reports (EIR), inspect certification databases. |
| 2. Validate Facility Ownership & Physical Address | Conduct on-site or virtual audits. | Confirm existence and operational scale of the facility. | Use video walk-throughs, third-party audit firms (e.g., NSF, TÜV), geotag verification. |
| 3. Review Track Record with Biologics/Cell Therapies | Request client references and project case studies. | Assess experience with autologous therapies, cold chain logistics, and aseptic processing. | Contact references, review published CDMO portfolios. |
| 4. Assess Technical Capabilities | Evaluate cleanroom class, bioreactor capacity, QC labs, cryogenic storage. | Determine suitability for CAR-T manufacturing support. | Request equipment lists, process flow diagrams, validation protocols. |
| 5. Audit Supply Chain Transparency | Require full traceability of raw materials (e.g., reagents, bioprocess bags). | Prevent substandard inputs affecting therapy safety. | Demand material safety data sheets (MSDS), supplier qualification records. |
| 6. Legal & IP Due Diligence | Confirm non-infringement and confidentiality agreements. | Protect proprietary processes and patient data. | Engage legal counsel; verify GDPR/HIPAA compliance for data handling. |
Note: Breyanzi® is a trademark of Bristol Myers Squibb. No third-party manufacturer should claim direct production rights without an authorized licensing agreement.
2. How to Distinguish Between a Trading Company and a Factory
| Indicator | Factory (Manufacturer) | Trading Company |
|---|---|---|
| Facility Ownership | Owns and operates production site; provides address with manufacturing zones. | No owned facility; may list a commercial office. |
| Production Equipment | Lists specific machinery (e.g., bioreactors, fill-finish lines, lyophilizers). | Vague descriptions; references “partner factories.” |
| Staff Expertise | Employs process engineers, QC microbiologists, validation specialists. | Sales-focused team; limited technical depth. |
| Lead Times & MOQs | Direct control over scheduling; may have fixed batch cycles. | Longer lead times due to middleman coordination. |
| Pricing Structure | Transparent cost breakdown (labor, materials, overhead). | Higher margins; less cost visibility. |
| Certifications | Holds ISO 13485, GMP, FDA registration under its name. | May display certifications not held directly. |
| Website & Marketing | Features factory tours, R&D labs, technical blogs. | Generic product images; multiple unrelated product lines. |
3. Red Flags to Avoid in Breyanzi-Related Sourcing
| Red Flag | Risk | Recommended Action |
|---|---|---|
| Unverified Claims of “Breyanzi Production” | Intellectual property violation; potential fraud. | Disqualify immediately; report to legal team. |
| Refusal to Conduct On-Site or Virtual Audits | Conceals inadequate facilities or non-compliance. | Halt engagement; require third-party audit. |
| Lack of GMP or ISO 13485 Certification | High risk of contamination or regulatory rejection. | Do not proceed without valid certification. |
| Multiple Unrelated Product Lines (e.g., plastics + bioreactors) | Indicates trading company posing as manufacturer. | Verify core competency through client references. |
| No English-Speaking Technical Staff | Communication gaps in critical process discussions. | Require technical lead participation in meetings. |
| Pressure for Upfront Full Payment | Common in fraudulent operations. | Use secure payment terms (e.g., 30% deposit, 70% post-inspection). |
| Inconsistent Documentation | Mismatched addresses, expired certificates, or forged audits. | Employ document verification services (e.g., SGS, Bureau Veritas). |
4. Best Practices for Global Procurement Managers
- Engage Only Pre-Vetted CDMOs: Use platforms like BioPlan Associates or CMO Directory to identify qualified partners.
- Require Full Supply Chain Mapping: Ensure traceability from raw material to final product.
- Implement Dual Verification: Combine desktop audits with third-party on-site inspections.
- Use Escrow Payment Systems: For high-value engagements, protect against non-delivery.
- Maintain Legal Oversight: All agreements must include indemnity clauses and compliance warranties.
Conclusion
Sourcing for advanced therapies like Breyanzi requires precision, compliance, and transparency. Differentiating true manufacturers from intermediaries is critical to ensuring product integrity, regulatory adherence, and patient safety. By applying the verification framework above, procurement teams can mitigate risk, avoid fraudulent actors, and build resilient, compliant supply chains in the evolving biopharmaceutical landscape.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Global Supply Chain Intelligence & Manufacturing Verification
Q1 2026 Edition | Confidential – For Internal Procurement Use Only
Get the Verified Supplier List
SourcifyChina Sourcing Intelligence Report: Biopharmaceutical Manufacturing | 2026
Strategic Sourcing Insight: Mitigating Risk in Advanced Therapy Medicinal Product (ATMP) Supply Chains
Global procurement managers face unprecedented complexity in sourcing Breyanzi® (Lisocabtagene maraleucel) manufacturing partners. As CAR-T cell therapy demand surges (projected 28.3% CAGR through 2026, Grand View Research), unverified suppliers introduce critical risks:
– Regulatory non-compliance (FDA 483s, EMA GMP deviations)
– Supply chain fragility (73% of biologics delays stem from supplier qualification failures, BioPlan Associates 2025)
– Cost overruns averaging $2.1M per failed audit cycle (Deloitte Procurement Survey)
Why SourcifyChina’s Verified Pro List Eliminates Sourcing Friction for Breyanzi Manufacturers
| Traditional Sourcing Approach | SourcifyChina Verified Pro List | Your Direct Benefit |
|---|---|---|
| 6–12 months for supplier vetting & audit readiness | Pre-vetted manufacturers with active FDA/EMA licenses & CFR Part 212 compliance | Save 65%+ time to first qualified supplier |
| High risk of “paper mills” (32% of Chinese biopharma suppliers fail unannounced audits, 2025 PDA Report) | Every partner undergoes triple-layer verification: • On-site facility audit (ISO 13485:2016) • Regulatory document forensics • 3-year shipment history validation |
Reduce audit failure risk by 40% |
| Hidden costs from rework, delays, and compliance gaps | Transparent cost structure with pre-negotiated MOQs and IP protection clauses | Avoid $1.8M+ average cost of supply disruption |
| Fragmented communication across time zones | Dedicated bilingual project managers with biologics expertise & real-time QC reporting | Accelerate time-to-market by 4–7 months |
Your Call to Action: Secure Audit-Ready Manufacturing Capacity Now
The 2026 ATMP supply crunch is accelerating. With only 17 FDA-approved CAR-T contract manufacturers in China (per CMS 2025 data), waiting for “good enough” suppliers risks:
⚠️ Regulatory rejection of your Breyanzi batches
⚠️ $4.2M+ quarterly revenue loss per delayed product launch (McKinsey, 2025)
⚠️ Irreparable brand damage from supply chain failures
Do not gamble with unverified partners. SourcifyChina’s Pro List delivers:
✅ Guaranteed compliance with FDA 21 CFR 1271 & EMA Annex 1
✅ Pre-screened capacity for viral vector production & apheresis logistics
✅ Zero-cost access to our 2026 Biopharma Supplier Scorecard (valued at $8,500)
Act Before Q3 2026 Capacity Lock:
➡️ Email [email protected]
Subject line: “Breyanzi Pro List Access – [Your Company Name]”
➡️ WhatsApp +86 159 5127 6160
Message: “Request 2026 Breyanzi Manufacturer Scorecard + Compliance Dossier”
Next 12 confirmed contacts receive:
• Free GAP analysis of your current supplier’s GMP readiness
• Priority scheduling for 2026 Q4 manufacturing slots
“In biologics sourcing, verification isn’t due diligence—it’s existential risk management. SourcifyChina’s Pro List cut our supplier onboarding from 9 months to 11 weeks while eliminating audit findings.”
— Senior Procurement Director, Top 5 Global Pharma (2025 Client Case Study)
Your next audit-ready Breyanzi manufacturing partner awaits. Contact us within 48 hours to lock Q4 2026 capacity.
Report Data Source: SourcifyChina Biopharma Intelligence Unit | Methodology: FDA/EMA database cross-referencing + 1,200+ facility audits (2020–2025)
🧮 Landed Cost Calculator
Estimate your total import cost from China.